- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1753 |
Product Name |
ADT1753-Human Anti-CD3xGPRC5D Bispecific Antibody |
Isotype |
Human IgG4-kappa |
Clonity |
Monoclonal |
|
Alternate Names Human Anti-CD3 mAb, Anti-CD3 Monoclonal Antibody, CD3 recombinant antibody, Anti-CD3 Bispecific Antibody, Human Anti-GPRC5D mAb, GPRC5D recombinant antibody, Anti-GPRC5D Monoclonal Antibody, Anti-GPRC5D Bispecific Antibody |
|
Official Symbol |
CD3xGPRC5D |
Target 1 |
CD3 |
Gene ID 1 |
916 |
Target 2 |
GPRC5D |
Gene ID 2 |
55507 |
Species |
Human |
Drug Name |
Talquetamab |
Endotoxin |
<1EU/mg. Determined by the LAL method. |
Sterility |
0.2 μM filtered. |
Expression Host |
CHO Cells |
CAS Number |
2226212-40-2 |
Chemical Formula |
C6410H9938N1716O2006S45 |
Molecular Weight |
147 KDa |
Product Description |
Talquetamab is a bispecific antibody used to treat adults with relapsed or refractory multiple myeloma. |
Mechanism of Action |
Talquetamab is a bispecific T-cell-engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and GPRC5D expressed on the surface of MM cells. It works to recruit CD3-expressing T cells to GPRC5D-expressing MM cells to induce T-cell–mediated cytotoxicity, prevent tumor growth, and promote tumor regression. When activated, T cells cause the release of proinflammatory cytokines, promoting the lysis of MM cells. |
Metabolism |
Talquetamab is expected to be metabolized into small peptides by catabolic pathways. |
Size |
1mg,5mg,50mg,100mg |
Research Area |
Cancer |
Application |
FuncS |
Purity |
>90% |
Concentration |
Batch dependent |
Buffer |
Supplied in PBS, pH 7.4,Contains no stabilizers or preservatives |
Recommended Dilution Buffer |
ABDB-1002 or PBS, pH 7.4, Contains no stabilizers or preservatives. |
Storage |
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
Shipping Condition |
Shipped on ice packs. |
Protocol Information |
Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. |
Note |
For Research Use Only! |
|
Reference 1. Pillarisetti K, Edavettal S, Mendonca M, Li Y, Tornetta M, Babich A, Majewski N, Husovsky M, Reeves D, Walsh E, Chin D, Luistro L, Joseph J, Chu G, Packman K, Shetty S, Elsayed Y, Attar R, Gaudet F: A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020 Apr 9;135(15):1232-1243. doi: 10.1182/blood.2019003342.
2. Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R, Sendecki J, Wong A, Verona RI, Sonneveld P, Zweegman S, Adams HC, Mutis T, van de Donk NWCJ: Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2196-2215. doi: 10.1182/bloodadvances.2020003805.
|
FAQ
-
+ -
What is GPRC5D, and why is it an emerging target for multiple myeloma?
GPRC5D (G protein-coupled receptor, class C, group 5, member D) is highly expressed in multiple myeloma cells but has limited expression in normal tissues. It is being targeted by bispecific antibodies and CAR-T therapies to enhance anti-myeloma activity.
-
+ -
How can I obtain COA of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
How does GPRC5D-targeted therapy compare to BCMA-targeted treatments?
While BCMA-targeted therapies are widely used in multiple myeloma, resistance can develop. GPRC5D-targeted therapies provide an alternative mechanism of action and are being explored for patients who relapse after BCMA-based treatments. -
+ -
How do bispecific antibodies compare to CAR-T therapy?
BsAbs act faster, are easier to manufacture, and lack the complexity of cell therapy. However, CAR-T offers durable responses, while BsAbs may require continuous dosing.